应用影像学方法评价乳腺癌新辅助化疗疗效

郭慧敏 ,  赵晋华

downloadPDF
文章导航 > 国际放射医学核医学杂志  > 2009,  33 > 3: (149-153)  
引用本文:
shu
Citation:
shu

应用影像学方法评价乳腺癌新辅助化疗疗效

  • 上海交通大学附属第一人民医院核医学科, 上海 200080

    • 通讯作者: 赵晋华, zjh1963@gmail.com

Imaging evaluation of breast cancer treated with neoadjuvant chemotherapy

  • Department of Nuclear Medicine, the First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China

    • Corresponding author: ZHAO Jin-hua, zjh1963@gmail.com

  • 摘要: 新辅助化疗治疗乳腺癌已经成为一种趋势,针对新辅助化疗的一系列研究正在开展。早期评价乳腺癌治疗疗效能避免对新辅助化疗无效者的过度治疗,支持有效者继续治疗。多种影像学评价方法相继应用于新辅助化疗的疗效评价。
    Abstract: Neoadjuvant chemotherapy for breast cancer has become a trend. A series of studies for it has been carrying out. Patients receiving ineffective treatment could be switched to alternative therapies and responding patients could receive more aggressive chemotherapy. Imaging modalities were of use in detecting the efficacy of neoadjuvant therapy. In this paper, a brief overview about imaging methods be performed.
  • [1] 左文述,徐忠法,刘奇.现代乳腺肿瘤学.2版.济南:山东科学技术出版社,2006:425.
    [2] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92(3):205-216.
    [3] Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer:comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol, 2004, 14(8):1371-1379.
    [4] Huber S, Medl M, Helbich T, et al. Locally advanced breast carcinoma:computer assited semiqutitative analysis of color Doppler uhrasonography in the evaluation of tumor response to neoadjuvant chemotherapy (work in progress). J Ultrasound Med, 2000, 19(9):601-607.
    [5] Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg, 1998, 176(6):502-509.
    [6] Londero V, Bazzocchi M, Ded Frate C, et al. Locally advanced breast cancer:comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol, 2004, 14(8):1371-1379.
    [7] Delille JP, Slanetz PJ, Yeh ED, et al. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy:noninvasive monitoring with functional MR Imaging pilot Study. Radiology, 2003, 228(1):63-69.
    [8] 顾雅佳,冯晓源,邱龙华,等.DWI对局部进展期乳腺癌新辅助化疗疗效评价的初步研究.放射学实践,2007,22(12):1249-1255.
    [9] 汪晓红,彭卫军,沈坤炜,等.fMRI监测乳腺癌新辅助化疗疗效的应用.放射学实践,2007,22(11):1135-1138.
    [10] Pickles MD, Lowry M, Manton DJ, et al. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat, 2005, 91(1):1-10.
    [11] 张晓鹏,李洁,孙应实,等.动态增强磁共振成像对乳腺癌新辅助化疗后病理反应性的术前评价.中国医学科学院学报,2008,30(1):98-103.
    [12] Rieber A, Zeitler H, Rosenthal H, et al. MR1 in breast cancer:influence of chemotherapy on sensitivity. Br J Radiol, 1997, 70(833):452-458.
    [13] Warren RM, Bobrow LG, Earl HM, et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy?. Br J Cancer, 2004, 90(7):1349-1360.
    [14] Rajan R, Poniecka A, Smith TL, et al. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer, 2004, 100(7):1365-1373.
    [15] Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat, 2004, 83(1):67-76.
    [16] 朱汇庆,林祥通,陈忠清,等.乳腺肿瘤摄取99Tcm-MIBI与预后因子的关系.中华核医学杂志,2002,22(1):19-21.
    [17] Dunnwald LK, Gralow JR, Ellis GK, el al. Residual tumor uptake of 99mTc-sestamibi after neoadjuvant chemotherapy for locally advanced breast carenoma prediets survival. Cancer, 2005, 103(4):680-688.
    [18] Takeuchi N, Fukumoto M, Nishioka A, et al. Seintigraphic prediction of response to chemotherapy in patients with breast cancer:Technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography. Int J Oncol, 2002, 20(1):53-58.
    [19] Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow changes by positron emission tomography:relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol, 2008, 26(27):4449-4457.
    [20] Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med, 2003, 44(11):1806-1814.
    [21] Smyczek-Gargya B, Fersis N, Dittmann H, et al. PET with[18F] fluorothymidine for imaging of primary breast cancer:a pilot study. Eur J Nucl Med Mol Imaging, 2004, 31(5):720-724.
    [22] Been LB, Elsinga PH, de Vries J, et al. Positron emission tomography in patients with breast cancer using 18F-3'-deoxy-3'-fluoro-L-thymidine (18F-FLT)-a pilot study. Eur J Surg Oncol, 2006, 32(1):39-43.
    [23] Pio BS, Park CK, Pietras R, et al. Usefulness of 3'-[F-18] fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol, 2006, 8(1):36-42.
    [24] Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography:initial evaluation. J Clin Oncol, 1993, 11(11):2101-2111.
    [25] Weber WA. Positron emission tomography as an imaging biomarke. J Clin Oncol, 2006, 24(20):3282-3292.
    [26] Schelling M, Avril N, Nährig J, et al. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol, 2000, 18(8):1689-1695.
    [27] Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol, 2006, 24(34):5366-5372.
    [28] McDermott GM, Welch A, Staff RT, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat, 2007, 102(1):75-84.
    [29] Doot RK, Dunnwald LK, Schubert EK, et al. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF. J Nucl Med, 2007, 48(6):920-925.
  • [1] 赵晋华 , 郭慧敏 . 综合应用临床影像学对乳腺癌进行筛查、诊断和分期. 国际放射医学核医学杂志, 2009, 33(4): 222-225. doi: 10.3760/cma.j.issn.1673-4114.2009.04.009
    [2] 隗功华 , 孙晓光 . 医学影像学在肿瘤治疗疗效评价中的应用. 国际放射医学核医学杂志, 2009, 33(1): 43-46. doi: 10.3760/cma.j.issn.1673-4114.2009.01.043
    [3] 董佳佳 , 章斌 . 多种影像学方法评价乳腺癌新辅助化疗疗效的价值比较. 国际放射医学核医学杂志, 2014, 38(6): 427-432. doi: 10.3760/cma.j.issn.1673-4114.2014.06.018
    [4] 夏晓天 , 张永学 . 影像学检查在乳腺癌的诊断及疗效评估中的应用价值. 国际放射医学核医学杂志, 2010, 34(4): 242-246, 249. doi: 10.3760/cma.j.issn.1673-4114.2010.04.014
    [5] 刘晓瑜 , 林翠君 , 黄洁 , 代海洋 . 不同分子分型乳腺癌的超声、MRI及乳腺X射线摄影特征的诊断价值. 国际放射医学核医学杂志, 2024, 48(2): 74-81. doi: 10.3760/cma.j.cn121381-202212013-00349
    [6] 冯学民 . 甲状腺癌的影像学研究进展. 国际放射医学核医学杂志, 2006, 30(5): 275-280.
    [7] 董华 , 张遵城 . 眼眶海绵状血管瘤的影像学分析. 国际放射医学核医学杂志, 2008, 32(1): 55-57,62.
    [8] 卢晓莉 , 张俊 , 王峰 , 王自正 . 影像学技术对转移性淋巴结的诊断价值. 国际放射医学核医学杂志, 2011, 35(6): 334-338. doi: 10.3760,cma.j.issn.1673-4114.2011.06.004
    [9] 李万婷 , 刘海燕 , 秦丽军 , 崔雅丽 , 牛静 , 武志芳 , 刘静 , 张国琛 , 任媛 , 李思进 . 99Tcm-3PRGD2整合素受体显像鉴别乳腺良恶性病变的价值及与超声检查的对比研究. 国际放射医学核医学杂志, 2018, 42(3): 242-247. doi: 10.3760/cma.j.issn.1673-4114.2018.03.009
    [10] 余丰文 , 冯彦林 , 贺小红 , 刘德军 , 温广华 , 袁建伟 . PET-CT与钼靶X线、B超定性诊断乳腺癌的临床对比研究. 国际放射医学核医学杂志, 2006, 30(3): 148-151.
    [11] 陈贵兵 , 欧阳忠 , 韩成坤 , 黄劲雄 , 何小江 , 王凡 , 贾兵 , 吴华 . 99Tcm-3PRGD2整合素受体显像在乳腺癌定性诊断中的价值及与钼靶检查的对比研究. 国际放射医学核医学杂志, 2017, 41(1): 1-7. doi: 10.3760/cma.j.issn.1673-4114.2017.01.001
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1766
  • HTML全文浏览量:  260
  • PDF下载量:  2
出版历程
  • 收稿日期:  2009-02-12

应用影像学方法评价乳腺癌新辅助化疗疗效

    通讯作者: 赵晋华, zjh1963@gmail.com
  • 上海交通大学附属第一人民医院核医学科, 上海 200080
  • 收稿日期: 2009-02-12

摘要: 新辅助化疗治疗乳腺癌已经成为一种趋势,针对新辅助化疗的一系列研究正在开展。早期评价乳腺癌治疗疗效能避免对新辅助化疗无效者的过度治疗,支持有效者继续治疗。多种影像学评价方法相继应用于新辅助化疗的疗效评价。

English Abstract

    全文HTML

参考文献 (29)

目录

    /

    返回文章
    返回

    版权所有©中华医学会   备案号：津ICP备15006720号-3

    地址：天津市南开区白堤路238号电话：86-22-58089989
    86-22-85682389    传真：022-87890607

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net